Nir Peled
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 105
- Lung Cancer Diagnosis and Treatment 37
- Oncology 92
- Cancer Immunotherapy and Biomarkers 52
- Lung Cancer Research Studies 22
- Colorectal Cancer Treatments and Studies 14
- Co-authors
- Rina Hui (16 shared papers)Delvys Rodríguez‐Abreu (17 shared papers)Andrew George Robinson (11 shared papers)Maya Gottfried (12 shared papers)Suman Rao (9 shared papers)Julie Renee Brahmer (9 shared papers)Katsuyuki Hotta (9 shared papers)Tibor Csőszi (9 shared papers)
- Journals
- Journal of Thoracic Oncology (49 papers)Annals of Oncology (22 papers)European Journal of Clinical Microbiology & Infectious Diseases (14 papers)Lung Cancer (11 papers)Journal of Clinical Oncology (7 papers)
- Partner nations
- IsraelUnited StatesGermany
In The Last Decade
Nir Peled
305 papers receiving 33.2k citations
Nir Peled's Hit Papers
Peers
Comparison fields: 5 of 167
- Oncology 16.4k
- Pulmonary and Respiratory Medicine 12.9k
- Cancer Research 3.8k
- Immunology 3.2k
- Pathology and Forensic Medicine 1.3k
Countries citing papers authored by Nir Peled
This map shows the geographic impact of Nir Peled's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nir Peled with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nir Peled more than expected).
Fields of papers citing papers by Nir Peled
This network shows the impact of papers produced by Nir Peled. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nir Peled. The network helps show where Nir Peled may publish in the future.
Co-authors
The 25 scholars most cited alongside Nir Peled, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 315 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 8178 |
| 2 | Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 5249 |
| 3 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma Hit paper breakdown → | 2018 | 1296 |
| 4 | Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Hit paper breakdown → | 2019 | 1292 |
| 5 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry Hit paper breakdown → | 2019 | 1055 |
| 6 | Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 842 |
| 7 | Volatile Organic Compounds of Lung Cancer and Possible Biochemical Pathways Hit paper breakdown → | 2012 | 810 |
| 8 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Hit paper breakdown → | 2021 | 802 |
| 9 | Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 610 |
| 10 | Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC Hit paper breakdown → | 2018 | 528 |
| 11 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Hit paper breakdown → | 2021 | 496 |
| 12 | Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Hit paper breakdown → | 2023 | 436 |
| 13 | Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules Hit paper breakdown → | 2016 | 431 |
| 14 | Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges Hit paper breakdown → | 2018 | 406 |
| 15 | Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 Hit paper breakdown → | 2021 | 323 |
| 16 | Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations Hit paper breakdown → | 2016 | 314 |
| 17 | 2017 | 298 | |
| 18 | 2017 | 290 | |
| 19 | 2017 | 267 | |
| 20 | 2019 | 216 |
About Nir Peled
Nir Peled is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery and Infectious Diseases, having authored 315 papers that have together received 33.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (105 papers), Cancer Immunotherapy and Biomarkers (52 papers), Lung Cancer Diagnosis and Treatment (37 papers), Cancer Genomics and Diagnostics (24 papers), Lung Cancer Research Studies (22 papers), Advanced Chemical Sensor Technologies (20 papers), Colorectal Cancer Treatments and Studies (14 papers) and Obstructive Sleep Apnea Research (10 papers). The work is most often cited by research in Oncology (16.4k citations), Pulmonary and Respiratory Medicine (12.9k citations), Cancer Research (3.8k citations), Immunology (3.2k citations) and Pathology and Forensic Medicine (1.3k citations). Nir Peled has collaborated with scholars based in Israel, United States and Germany. Frequent co-authors include Rina Hui, Delvys Rodríguez‐Abreu, Andrew George Robinson, Maya Gottfried, Suman Rao, Julie Renee Brahmer, Katsuyuki Hotta, Tibor Csőszi, Ali Reza Tafreshi and Sinead D. Cuffe. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, European Journal of Clinical Microbiology & Infectious Diseases, Lung Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.